In addition, in recent years, the treatment of residual disease after NAC in HER-2 positive and triple negative breast cancer has been shown to contribute to survival, and NAC applications have become more preferred and applied in earlier stages15,16. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.